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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S337Conclusion: PGRN plays a chondroprotective role in the pathogenesis
of OA, through a) inhibiting TNFa-induced catabolic and b) activating
anabolic metabolism as a novel chondrogenic growth factor.
Fig. 3. The protective role of PRGN in surgically-induced osteoarthritis A)
PGRN-/-mice showed elevated degradation of cartilage in DMM model. B)
Intra-articular injection of PRGN reduces the loss of proteoglycan in sur-
gically induced OA.
Figure 1. PGRN effectively prevents the loss of cartilage by TNF-a. Total
RNA was extracted and real-time polymerase chain reaction (PCR) was
performed using a sequence-speciﬁc probe and primers for MMP13 (a),
RUNX2 (b), COX-2 (c) and iNOS (d). Each was tested under three con-
ditions (control, TNF-a and TNF-awith PGRN). Our results demonstrated a
drastic decrease in all metabolic levels with the induction of PGRN (Figure
4.a, b, c, d).
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TNFa IS A CRITICAL MEDIATOR OF SYNOVIAL HYPERPLASIA AND
OSTEOPHYTE FORMATION IN HIGH FAT-FED MICE
R.A. Mooney, D. Hamada, R. Maynard, S.L. Kates, M.J. Zuscik. Univ. of
Rochester Med. Ctr., Rochester, NY, USA
Purpose: Obesity and associated type 2 diabetes are important risk fac-
tors for osteoarthritis (OA). A critical hallmark of themetabolic disease ofdiabetes is a low-grade chronic inﬂammation. Evidence indicates that the
proinﬂammatory cytokine TNFa plays an important role inmediating the
metabolic dysfunction in this state. Inﬂammation is now also recognized
to be a contributing factor in the pathogenesis of osteoarthritis. Here we
use human ﬁbroblast-like synoviocytes (FLS) and mouse models to test
thehypothesis that TNFaplays an important role inmediating theadverse
effects of obesity and type 2 diabetes on two aspects of OA progression:
synovial hyperplasia and osteophyte formation.
Methods: Animals: Male C57BL/6J (wild type) mice were bred from
existing colonies and age matched to TNFa-/- mice (Jackson Labs). Mice
were placed on high-fat (HF, 60% kcal, D12492) or low-fat (LF, 10% kcal,
D12450B) diets at 5 weeks of age (Open Source Diets, Research Diets).
Mice were continued on their diets for 24 weeks before sacriﬁce and
harvest. Histology: Following sacriﬁce, knee joints were isolated and
formalin ﬁxed, decalciﬁed, and embedded in parafﬁn. Sagittal sections
were stained with Alcian blue-hematoxylin before assessment. Synovial
samples: Human FLSs were isolated from the synovial tissues of OA
patients undergoing total knee arthroplasty. FLSs were serum-starved
overnight prior to 24h treatment with cytokine and insulin. Total RNA
was extracted from FLSs and gene expression quantitated by qRT-PCR.
Results: Immunohistochemistry demonstrated that while TNFa and
BMP2 were not detected in the synovium of LF fed mice, there was
strong synovial expression of both genes in mice fed the HF diet. This
increased expression was associated with synovial hyperplasia and
increased formation of osteophytes. To investigate these potential
mediators of HF diet-associated osteoarthritis more directly, the
response of human FLSs to TNFa was examined. In response to TNFa
treatment, expression of BMP2 and TNFa was increased 6 and 40-fold,
respectively, as measured by qRT-PCR. The latter result suggests a feed
forward ampliﬁcation of TNFa. Importantly, insulin inhibited the effects
of TNFa on BMP2 expression by approximately 50%. To assess the in vivo
effect of TNFa, TNFa knockout mice were placed on the HF and LF diets
for 24weeks. As expected, absence of TNFa blunted theweight gain and
the glucose intolerance that is observed in HF diet fed mice. In LF fed
TNFa-/- mice, osteophyte numbers and synovial hyperplasia were
modestly increased above baseline, suggesting a role for TNFa in joint
maintenance under control conditions. Importantly, the increase in
osteophyte number and synovial hyperplasia present in HF-fed wild
type mice was completely absent in HF TNFa-/- mice, supporting a
pathogenic role for TNFa in osteoarthritis during HF diet consumption,
obesity, and type 2 diabetes/systemic inﬂammation.
Conclusions: TNFa plays an important role in the weight gain and
metabolic dysregulation of HF diet-associated obesity and type 2 dia-
betes. TNFa also promotes expression of osteoarthritis-associated
cytokines by FLSs, which can be reversed by insulin treatment, sug-
gesting a protective role for insulin in synovial joints. Finally, the
TNFa-/- mouse model conﬁrms the critical role of TNFa in the patho-
genesis of synovial hyperplasia and osteophyte formation in HF-fed,
obese and diabetic mice.
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SHORT BUT NOT LONG TERM SCLEROSTIN INHIBITION WORSENS
POST-TRAUMATIC OSTEOARTHRITIS IN MICE
B.Y. Chan, S. Zaki, S. Smith, M. Smith, C.B. Little. Raymond Purves Res.
Labs, Kolling Inst. of Med. Res., The Univ. of Sydney, St Leonards, Australia
Purpose: Sclerostin (SOST) and dikkopf-1 (DKK1) are secreted proteins
that inhibitWnt signaling. IncreasedWnt-b-catenin activity is implicated
in cartilage degradation in osteoarthritis (OA), at the same time driving
increased bone formation (subchondral thickening, osteophytes) that
typiﬁes OA. This suggests that increasing SOST/DKK1 may be protective
while inhibiting these Wnt antagonists may worsen OA cartilage and
bone pathology. A recent report found that over-expression of DKK1 in
chondrocytes did indeed reduce cartilage and bone pathology in post-
traumatic (pt)OA in mice, however in another study systemic SOST
inhibition did not alter ptOA cartilage erosion in rats. Whether these
different outcomes relate to the inhibitor targeted and their systemic
versus cell-speciﬁc regulation, or the species and ptOA model used is
unclear. The present study examined whether systemic inhibition of
SOST changed ptOA pathology in mice induced by the same meniscal
destabilization (DMM) model as in the DKK1 over-expression study.
Methods: Forty-eight 10-week male C57BL6 mice had unilateral DMM
surgery andwere randomly assigned to receive 20mg/kg of anti-SOSTor
control IgG antibody (provided by Eli-Lilly) subcutaneously twice
weekly: from the day of surgery and sacriﬁced at 4 (group 1) or 8 (group
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weeks (group 2) (n ¼ 8/antibody/group). At sacriﬁce knees were ﬁxed,
bone changes analysed by mCT, joints then decalciﬁed and OA pathology
scored (average of 2 blinded observers) on serial sagittal sections. SOST
and DKK1 were immunolocalized in 3 mice of each group/antibody.
Results: Treatments were well tolerated with no adverse reactions
observed; all animals completed the study. The signiﬁcant effects of
anti-SOST compared with IgG in operated limbs from the 3 groups are
summarized in Table 1. Increased tibial cortical bone thickness and
subchondral trabecular bone volume were seen by mCT in all groups
with anti-SOST compared with IgG (p<0.05), conﬁrming the efﬁcacy of
the SOST inhibition. However, subchondral bone plate thickness was
only increased by anti-SOST in groups 1 and 2 (p<0.05). Similarly,
histological scoring of subchondral bone sclerosis was only signiﬁcantly
increased with short-term SOST inhibition (groups 1 and 2). Inhibition
of SOST only later in ptOA development (group 2) led to increased
osteophyte size (p<0.05). Importantly, this later anti-SOST treatment
(group 2) also increased articular cartilage structural damage (p<0.05).
Immunohistochemistry revealed that anti-SOST antibody increased the
number of SOST positive cells in calciﬁed cartilage (x24-86%) and sub-
chondral bone (x33-124%) in all groups. While short term SOST inhib-
ition (groups 1 and 2) also increased DKK1 positive cells throughout the
cartilage (x47-180%) and subchondral bone (x250-260%), long-term
SOST blockade (group 3) reduced DKK1 positive cells in all tissues (to
30-60%).
Conclusion: Blocking SOST by systemic administration of a monoclonal
antibody had detrimental effects on the progression of DMM-induced
ptOA in mice. Importantly the effect was dependent on timing, being
more pronounced with short-term administration and particularly
when given later in disease. It is unclear whether the increase in car-
tilage damage (group 2), was a direct effect of anti-SOST on chon-
drocytes, inhibition of synovial SOST, or indirectly through changing
subchondral bone. That long-term SOST-blockade did not alter joint
pathology to the same extent as short-term treatment may be related to
different compensatory changes in other Wnt-regulatory proteins as
seen with DKK1. The temporal difference in SOST blockade in joint
versus distant skeleton may reﬂect when SOST expression in OA is most
pronounced and/or when increases in subchondral bone plate are most
rapid or important in disease progression. The latter may also explain
differences in our ﬁndings compared with those reported in rat ptOA,
where more pronounced and prolonged bone loss occurs. Improved
understanding of the regulation of Wnt signaling in different skeletal
and joint tissues with time, may lead to novel therapeutic approaches in
OA.Table 1
Parameters signiﬁcantly increased in anti-SOST compared to IgG treated mice (+ ¼ p < 0.05, - ¼ no change).
Micro CT Histology score
Cortical Bone Subchondral Trabecular Bone Subchondral Bone Plate Subchondral Bone Plate Osteophyte Size Articular cartilage Erosion
Group 11-4 weeks + + + + - -
Group 24-8 weeks + + + + + +
Group 31-8 weeks + + - - - -591
IDENTIFICATION OF GREMLIN1 AS A CATABOLIC FACTOR INDUCED
BY MECHANICAL STRESS LOADING IN ARTICULAR CHONDROCYTES
S. Chang y, H. Kobayashi y, K. Okada y, S. Sugita y, T. Okuma y, Y. Mori y,
M. Kawata y, S. Tanaka y, H. Kawaguchi z, T. Saito y. y The Univ. Of Tokyo,
Tokyo, Japan; z Spine Ctr., Tokyo Kosei Nenkin Hosp., Tokyo, Japan
Purpose: Excessive mechanical stress loading on articular cartilage is
one of the major factors of osteoarthritis (OA); however, the molecular
mechanisms of cartilage degradation by such loading remain unclear.
The present study therefore analyzed gene expression proﬁles of
articular chondrocytes under mechanical stress loading and inves-
tigated functions of the candidate gene.
Methods: To load mechanical stress on cultured chondrocytes, we used
a programmable cell stretcher system, STB-140 (STREX). Primary
articular chondrocytes from 5-day-old mouse knee joints were seeded
onto stretch chambers at a concentration of 1.0106 cells/chamber.
After 48 h of culture on the chambers, we initially applied a uni-axial
cyclic cell stretch (0.5 Hz, 10% stretch) to the articular chondrocytes for
30 min, then cultured them for an additional 24 h. cDNA microarray(SurePrint G3, Agilent Expression Array) analyses were performed using
samples before and after the mechanical loading. The gene expressions
were conﬁrmed by real-time RT-PCR and immunohistochemistry. The
catabolic ability was assessed by measuring the concentration of
aggrecan released from cultured 3-week-old mouse femoral heads
using the dimethylmethylene blue dye-binding assay. We used mouse
primary articular chondrocytes and mouse chondrogenic cell line
ATDC5 for further in vitro functional analyses.
Results: Microarray analyses revealed that 2,076 genes were increased
more than twice by the mechanical stress loading. Among them, we
focused on Gremlin1, which is one of the most highly expressed genes.
Gremlin1 is known to be a secreted protein that regulates limb devel-
opment as a BMP antagonist during skeletal development, although its
function in articular cartilage is unknown. Immunohistochemistry
revealed that Gremlin1 protein was localized in cytoplasm of mouse
normal knee articular chondrocytes, and the expression was enhanced
in the cells of the experimental mouse OAmodel. In the organ culture of
mouse femoral heads, recombinant human (rh) Gremlin1 treatment
increased aggrecan release into the medium in a dose-dependent
manner. In primary culture of mouse articular chondrocytes, rhGrem-
lin1 treatment induced the expressions of catabolic factors including
Mmp13 and Adamts5, and suppressed those of anabolic factors
including Col2a1, aggrecan and Sox9. Lentiviral overexpression of
Gremlin1 in ATDC5 cells also induced the catabolic factor expressions
and suppressed the anabolic factor expressions. In organ culture of
mouse femoral heads, rhBMP-7 treatment decreased the aggrecan
release, and this anti-catabolic effect was abolished by the co-treatment
of rhGremlin1. To further identify other signals related to the catabolic
effect of Gremlin1 under the mechanical stress, we performed pathway
analyses and gene ontology analyses using the microarray data and
Genespring software, and found the NF-kB signal to be the most potent
candidate pathway associated with both mechanical stress loading and
Gremlin1. To know the involvement of the NF-kB signal with the
catabolic effect by Gremlin1, we used conditional knockoutmice of Rela,
a representative transcription factor of the NF-kB signal. In the organ
culture of femoral heads from Col2a1-Cre;Relaﬂ/ﬂmice, rhGremlin1 did
not induce the aggrecan release, while it normally induced the release
in the control Relaﬂ/ﬂ femoral heads. We further conﬁrmed that sup-
pression of the NF-kB signal by an IKK inhibitor (BMS-345541) treat-
ment also diminished the increase of aggrecan release. Induction of
catabolic factors and suppression of anabolic fators by rhGremlin1 were
also diminished by the IKK inhibitor treatment.
Conclusion: We have identiﬁed Gremlin1 as a catabolic factor induced
by the mechanical stress loaded to articular chondrocytes, not onlythrough the BMP signal but also through the NF-kB signal. Gremlin1
may provide a novel therapeutic target of OA.
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A ROLE FOR TGFb-RII/MCP-5 AXIS DURING POST TRAUMATIC
OSTEOARTHRITIS AND POTENTIAL ROLE OF PTHRP IN MEDIATING
MCP-5 EFFECT
L. Longobardi y, J.D. TempleN.D’Onofrio z,x, H. Ozkan k, A. Esposito y,
H. Willcockson y, T. Li y, T.J. Myers y, P. Ye y, B.M. Moats-Staats y,
M. Balestrieri x, A. Spagnoli y. yUniv. of North carolina at Chapel Hill,
Chapel Hill, NC, USA; zUniv. of North Carolina, Chapel Hill, NC, USA;
x Second Univ. of Naples, Naples, Italy; kGulhane Military Med. Academy,
Ankara, Turkey
Purpose: In previous studies we found that the down-regulation of the
chemokine MCP5 by TGF-b Type II receptor (TbRII) signaling is required
for joint development. MCP-5 role in arthritis is demonstrated by
human and animal studies. MCP-5, its human homologous MCP-1 and
their sole common receptor CCR2, are increased in the inﬂamed joints
